BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26030920)

  • 1. Amino Acid Substitutions Improve the Immunogenicity of H7N7HA Protein and Protect Mice against Lethal H7N7 Viral Challenge.
    Kumar SR; Prabakaran M; Ashok Raj KV; He F; Kwang J
    PLoS One; 2015; 10(6):e0128940. PubMed ID: 26030920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.
    Rajesh Kumar S; Syed Khader SM; Kiener TK; Szyporta M; Kwang J
    PLoS One; 2013; 8(6):e63856. PubMed ID: 23762234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
    Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
    Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
    Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
    Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
    Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
    Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.
    Min JY; Vogel L; Matsuoka Y; Lu B; Swayne D; Jin H; Kemble G; Subbarao K
    J Virol; 2010 Nov; 84(22):11950-60. PubMed ID: 20810733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.
    Musthaq SK; Kumar SR; Szyporta M; Kwang J
    Antiviral Res; 2014 Sep; 109():42-53. PubMed ID: 24973759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.
    Khurana S; Chung KY; Coyle EM; Meijer A; Golding H
    J Virol; 2016 Oct; 90(20):9383-93. PubMed ID: 27512055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
    Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice.
    Tang LH; Lim JH; Kuah LF; Lau YF
    Vaccine; 2014 Sep; 32(42):5375-8. PubMed ID: 25130540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
    Chen Z; Baz M; Lu J; Paskel M; Santos C; Subbarao K; Jin H; Matsuoka Y
    J Virol; 2014 Jun; 88(12):7016-23. PubMed ID: 24719414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.
    Valkenburg SA; Li OT; Mak PW; Mok CK; Nicholls JM; Guan Y; Waldmann TA; Peiris JS; Perera LP; Poon LL
    Proc Natl Acad Sci U S A; 2014 Apr; 111(15):5676-81. PubMed ID: 24706798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.
    Ito M; Yamayoshi S; Murakami K; Saito K; Motojima A; Nakaishi K; Kawaoka Y
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30754701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
    El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
    Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice.
    Xu L; Bao L; Lau SY; Wu WL; Yuan J; Gu S; Li F; Lv Q; Xu Y; Pushko P; Chen H; Qin C
    Vaccine; 2016 May; 34(23):2627-33. PubMed ID: 27083426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.